Macitentan not checked

Actelion · ACT-064992 · JNJ-67896062

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
37 in total · 5 in the EU

What this is

How it works
Blocks endothelin, a signal that tightly narrows blood vessels.Endothelin Receptor Antagonist FDA class
How it’s given
“Participants will receive macitentan 37.5 mg film-coated tablets orally.”In the company’s words, NCT04273945 on ClinicalTrials.gov
Tested for
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Main trialPhase 3
“The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.”In the company’s words, NCT04273945 on ClinicalTrials.gov
Other names
Opsumit · ACT-064992 · JNJ-67896062 · ACT-064992D · Active drug · ZEPENDO

Other drugs for Pulmonary Arterial Hypertension

All 24 drugs for Pulmonary Arterial Hypertension

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials37

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 7 Oct 2025 Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Phase 3Recruiting 31 Jan 2027 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Phase 4Completed 25 Oct 2017 PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Phase 4Completed 10 Sep 2019 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
Phase 3Terminated Feb 2014 Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Phase 3Completed 19 Sep 2018 Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Phase 3Completed 29 Aug 2019 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Phase 3Terminated 29 Jun 2020 A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Phase 3Completed 7 Dec 2020 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Phase 3Completed 30 Jun 2021 Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
Phase 3Terminated 18 Jan 2022 An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
Phase 3Completed 23 Aug 2022 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Phase 3Terminated 21 Dec 2023 A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Phase 3Completed 27 Dec 2023 A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
Phase 3Completed 23 Aug 2024 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
Phase 3Completed 28 Aug 2024 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
Phase 2Withdrawn 31 Aug 2016 Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
Phase 2Completed 28 Sep 2016 Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Phase 2Completed 13 Mar 2020 Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Phase 2Completed 12 Mar 2021 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase 2Terminated 12 Oct 2021 A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase 2Completed 21 Mar 2022 Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Phase 1Completed Nov 2011 Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects
Phase 1Completed Dec 2015 Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults
Phase 1Completed 24 Sep 2017 A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects
Phase 1Completed 4 Dec 2017 Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects
Phase 1Completed 17 Jul 2020 A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
Phase 1Completed 14 Dec 2020 A Study of Macitentan, in Healthy Japanese Male Participants
Phase 1Completed 19 Apr 2021 A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
Phase 1Completed 8 Aug 2021 A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
Phase 1Completed 12 Sep 2021 A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants
Phase 1Completed 13 May 2022 A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants
Phase 1Completed 30 Aug 2022 A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants
Phase 1Completed 31 Aug 2022 A Study of Two Macitentan Formulations in Healthy Adult Participants
Phase 1Withdrawn 1 Apr 2024 A Study of Macitentan in Children Below 2 Years of Age
Phase 1Ended not given A Phase 1, Prospective, Cross-over, Double-blind Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants
Phase 2Ended not given IMPACT-CTEPH Initial dual oral coMbination therapy versus standard-of-care initial oral monotherapy Prior to balloon pulmonary Angioplasty in patients with inoperable Chronic thromboembolic pulmonary hyperTension”
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Macitentan

Following is part of Solo: you see every change to Macitentan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in